Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 1 · 14.3%Moderate 4 · 57.1%High 0 · 0%

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.93 [0.83, 1.04]
5 studies · 2006 participants
Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Progression‐free survival · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy probably leads to lower progression‐free survival (PFS) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.81 [0.74, 0.89]
5 studies · 2006 participants
Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 608 participants
Low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall severe adverse events (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.11 [0.95, 1.3]
2 studies · 834 participants
Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Anaemia (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.37 [1.02, 1.85]
5 studies · 1961 participants
Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Hand‐foot syndrome (grade ≥ 3) · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings 1: PLD with chemotherapy changes hand‐foot syndrome (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 4.01 [1, 16.01]
2 studies · 1028 participants
Very low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Neurological (grade ≥ 3) · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings 1: PLD with chemotherapy changes neurological (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 0.38 [0.2, 0.74]
4 studies · 1900 participants
Very low